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Sema3E, a ligand for PlexinD1, controls angiogenesis and promotes cancer invasion and metastasis. In this
issue of Cancer Cell, Luchino and colleagues report that Sema3E also ensures breast cancer cell viability
by blocking a previously unknown proapoptotic signaling cascade elicited by unliganded PlexinD1, thus
behaving as a ‘‘dependence receptor.’’Semaphorins are a large family of extra-
cellular signals implicated in a range of
developmental and physiological pro-
cesses and also in cancer (Tamagnone,
2012). Semaphorin 3E (Sema3E) is a
secreted member whose recognized
receptor is PlexinD1. In addition to pro-
viding restrictive cues for angiogenesis,
Sema3E-PlexinD1 signaling can regulate
other cell types. However, there is not a
unique intracellular pathway involved,
and multiple effectors have been pro-
posed, depending on cell context (Gay
et al., 2011). Various reports implicate
PlexinD1-dependent regulation of mono-
meric GTPases, leading to the inhibition
of integrin-mediated cell-substrate adhe-
sion; this is thought to regulate directional
cell migration and, possibly, consensus
signals for cell viability (e.g., in the
endothelial lining of blood vessels). Addi-
tional studies have demonstrated that
Sema3E-PlexinD1 signaling may mediate
opposite functions in other contexts due
to the involvement of PlexinD1-associ-
ated tyrosine kinases. This was shown
by the Mann group in distinct populations
of CNS neurons, which responded to
Sema3E by either attraction or repulsion,
depending on Nrp1 expression and
VEGFR2 tyrosine kinase activation in
association with PlexinD1 (Bellon et al.,
2010). Notably, Sema3E does not activate
VEGFR2 in endothelial cells, suggesting
that functional coupling between plexins
and tyrosine kinase receptors is ruled by
mechanisms awaiting clarification. Fur-
thermore, it was shown that Sema3E
can induce the invasive and metastatic
behavior of tumor cells by coupling
PlexinD1 with the oncogenic tyrosine
kinases ErbB2 and EGFR (Casazza
et al., 2010).
In this issue of Cancer Cell, Luchino
et al. (2013) report a novel function of564 Cancer Cell 24, November 11, 2013 ª20Sema3E in cancer cells in preventing
apoptotic cell death, potentially providing
an alternative mechanism to account
for its tumor- and metastasis-promoting
function. The authors find increased
Sema3E expression in advanced and
metastatic human breast tumors, consis-
tent with reports in colorectal carcinoma,
melanoma, and ovarian cancer (Casazza
et al., 2010; Tseng et al., 2011). Interest-
ingly, in this and other studies, PlexinD1
expression was also found to be consis-
tently high in human tumors compared
to normal tissues (Roodink et al., 2009),
potentially supporting the relevance of
an autocrine/paracrine Sema3E circuit in
tumor progression.
The work of Luchino et al. (2013) is
particularly exciting, because it proposes
a new mechanism responsible for these
functions. The authors found that ectopic
PlexinD1 overexpression in nonmalignant
HEK293T cells induced a significant
increase in apoptosis, which was abro-
gated upon addition of Sema3E. The
effect is mediated by the cytoplasmic
domain of PlexinD1, but seems to be
independent from the above-mentioned
integrin regulatory activity. This paradigm
fits with that of so-called ‘‘dependence re-
ceptors,’’ such as DCC, which mediate
cell death signals basally that are blocked
when ligand is present (Goldschneider
and Mehlen, 2010). According to this
paradigm, cells expressing dependence
receptors either establish an autocrine
ligand loop or become dependent on
paracrine signals in the microenvironment
for survival. For PlexinD1, the paradigm
was validated by finding increased
(PlexinD1-dependent) apoptosis in breast
carcinoma cells subjected to Sema3E
downregulation. Notably, Sema3E defi-
ciency does not prevent cancer cell prolif-
eration. The authors report unpublished13 Elsevier Inc.data in agreement with previous studies
showing that Sema3E-depleted cells
grow in vitro and are equally tumorigenic
in mice, although their invasive and meta-
static behavior is impaired (Casazza et al.,
2010; Tseng et al., 2011). Luchino and
coworkers explain this apparent con-
tradiction by postulating that a subpopu-
lation of Sema3E-deficient cells capable
of escaping PlexinD1-mediated death
signals could emerge and be positively
selected in culture (Luchino et al., 2013).
Indeed, while PlexinD1 expression is quite
widespread in tumor cells, Sema3E levels
are much more discordant; thus, future
studies may reveal mechanisms confer-
ring independence from Sema3E survival
signals. Of note, another putative ligand
binding PlexinD1 with lower affinity,
Sema4A, did not prove particularly active
as an alternative blocker of PlexinD1-
induced death signals.
To elucidate the pathway eliciting
cell death downstream of PlexinD1,
the authors identified an interactor of
PlexinD1’s cytoplasmic domain NR4A1/
Nur77 and showed that this association
is abrogated in the presence of Sema3E.
The role of NR4A1 in the apoptotic
response was confirmed by gene silenc-
ing, but the implicated molecular mecha-
nisms are only partly understood. In
presence of PlexinD1, NR4A1 may act at
the mitochondria to promote apoptosis;
however, it remains unclear how Sema3E
can regulate this pathway. Unliganded
‘‘dependence receptors’’ are known to
undergo proteolytic cleavage releasing
an intracellular portion implicated in the
death signaling cascade (Goldschneider
and Mehlen, 2010). However, this is not
shown for PlexinD1. Instead, full-length
PlexinD1 interacts with NR4A1, suggest-
ing its recruitment at the cell surface.
Future studies could analyze potential
Figure 1. Sema3E-PlexinD1 Interactions Have Context-Dependent Consequences
(A) Sema3E binding to PlexinD1 can promote cancer invasion and metastasis. However, Sema3E
becomes essential for cell viability when NR4A1 is associated with PlexinD1. Thus, in the presence of
NR4A1, PlexinD1 acts as a ‘‘dependence receptor.’’
(B) The soluble extracellular portion of PlexinD1 (called SD1) was used as a Sema3E ligand trap. SD1
competes against transmembrane PlexinD1 for Sema3E binding, leaving this ‘‘dependence receptor’’
unliganded, which results in the apoptosis of cancer cells expressing high level of PlexinD1.
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Previewscorrelations between PlexinD1, Sema3E,
and NR4A1/Nur77 expression in human
tumors. NR4A1/Nur77 was previously
found downregulated in metastatic breast
cancer, and this could account for a loss
of Sema3E dependence in PlexinD1-
overexpressing tumors (Figure 1A). More-
over, endothelial cells also express high
levels of PlexinD1; thus, it will be inter-
esting to study the relevance of this path-
way in endothelial cells and other stromal
cells in the tumor microenvironment.
It was reported previously that interfer-
ence with Sema3E signaling in preclinical
mouse models can achieve a remarkable
reduction of tumor growth and meta-
static spreading by combined inhibitionof cancer cells and tumor vasculature
(Casazza et al., 2012; Sabag et al.,
2012). Here, Luchino et al. (2013) targeted
tumor development by blocking survival
signals mediated by Sema3E in breast
cancer cells. This was achieved by over-
expressing in tumor cells a soluble portion
of the extracellular domain of PlexinD1,
called SD1, capable of sequestering
Sema3E and preventing receptor binding
(Figure 1B). The affinity of this decoy re-
ceptor for Sema3E is low compared to
full-length PlexinD1; however, on treat-
ment with concentrated SD1, cancer cells
underwent apoptosis, an effect that was
specifically prevented by little amounts
of Sema3E. Upon stable transfection ofCancer Cell 24, NSD1, the growth of 4T1 cancer cells was
inhibited due to the accumulation of the
ligand trap in the conditioned medium.
The authors do not provide evidence
in vitro that SD1 activity is due to un-
leashing PlexinD1-dependent cell death
signals. However, whereas SD1 overex-
pression in tumor cells strongly inhibited
their growth in mice, tumors formed by
PlexinD1-deficient cells were not affected
by SD1. Thus, according to this model,
downregulating PlexinD1 expression
seems to be ideally suited to make tumor
cells independent of Sema3E. Actually,
PlexinD1 expression is rarely low in
tumors and immortalized cancer cells,
which supports the view that PlexinD1
can also independently elicit tumor-
promoting signaling cascades in pres-
ence of the ligand. Moreover, although
tumor vessels are known to express
high levels of PlexinD1, they did not
seem to be affected by SD1, which sug-
gests that PlexinD1-induced death sig-
naling is possibly a cancer cell-selective
mechanism.
In a final set of experiments, Luchino
etal. (2013) administeredpurifiedSD1pro-
tein systemically to tumor-bearing mice.
Consistent with applying a competitor
mutated isoform of Sema3E (Casazza
et al., 2012; Sabag et al., 2012), this
approach led to significant reduction of
tumor growth and metastatic dissemina-
tion, confirming that Sema3E signaling in
the tumor microenvironment is a relevant
therapeutic target to inhibit tumor progres-
sion. In perspective, further improved
molecular tools might be developed for
thispurpose.For instance, function-block-
ing antibodies are broadly applied in anti-
cancer targeted therapy, and the potential
efficacy of Sema3E- or PlexinD1-targeted
antibodies will hopefully be tested in the
future. Importantly, this new study ex-
pands the functions and signaling mecha-
nisms potentially mediated by Sema3E in
different tumor types; hence, efforts
should be put into identifying the best
applicable interfering tools in diverse
characterized preclinical settings.REFERENCES
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